Pluvicto
Chemical Name | lutetium (177Lu) vipivotide tetraxetan |
Dosage Form | Injection (intravenous; 1000 MBq/mL (27 mCi/mL)) |
Drug Class | Radioactive therapeutic agents |
System | Male reproductive |
Company | Advanced Accelerator Applications |
Approval Year | 2022 |
Indication
- For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy